An open-label, dose-escalation, phase I study of AVE9633 administered as an intravenous infusion to patients with relapsed or refractory CD33-positive acute myeloid leukaemia

Trial Profile

An open-label, dose-escalation, phase I study of AVE9633 administered as an intravenous infusion to patients with relapsed or refractory CD33-positive acute myeloid leukaemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2007

At a glance

  • Drugs AVE 9633 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Dec 2007 Interim results were reported at ASH in December 2007.
    • 19 Jan 2007 Interim results have been reported.
    • 19 Jan 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top